BridgeBio Q3 net loss $177M; acoramidis NDA filing by year-end

BridgeBio Pharma, Inc.

2023-Q3 EPS reported -$2.99 revenue$7,558,000

Net loss attributable to common stockholders $177M ($1.08 per share) vs $137M ($0.93) YoY.
Revenue $4.1M, up from $0.3M YoY; operating costs $161.8M vs $129.5M.
Cash, equivalents, marketable securities $505.2M; raised $316M gross via ATM and PIPE.
NDA for acoramidis (ATTR-CM) to be filed with FDA by end of 2023; Phase 3 win ratio 1.8 (p<0.0001).
Regulatory alignment with FDA/EMA for infigratinib in achondroplasia; Phase 3 trial start expected in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BridgeBio Pharma, Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 2, 2023, BridgeBio Pharma, Inc. reported recent business updates and its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-057745

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.